Cost-effectiveness of nivolumab in patients with advanced renal cell carcinoma treated in the United States.

ABSTRACT:

Background

We evaluated the cost-effectiveness of nivolumab versus everolimus in patients with advanced renal cell carcinoma (RCC) from a US payer perspective.

Methods

A partitioned survival model consisting of three health states, progression-free survival (PFS), progressive disease, and death, was developed to evaluate the cost-effectiveness of intravenous nivolumab versus oral everolimus over a lifetime. The proportion of patients in each state was calculated based on parametric distributions fitted to PFS and overall survival (OS) data from CheckMate 025 (N = 821), a large randomized phase 3 trial of nivolumab versus everolimus for advanced RCC. Health state utility data were derived from CheckMate 025 EQ-5D data. Scenario analyses and deterministic and probabilistic sen

SUBMITTER: McCrea C 

PROVIDER: S-EPMC5810189 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature